Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000175405 | SCV000226881 | uncertain significance | not provided | 2014-12-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763750 | SCV000894636 | uncertain significance | Alternating hemiplegia of childhood 1; Migraine, familial hemiplegic, 2 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001852147 | SCV002162309 | uncertain significance | Familial hemiplegic migraine | 2022-11-08 | criteria provided, single submitter | clinical testing | This sequence change replaces methionine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 892 of the ATP1A2 protein (p.Met892Thr). This variant is present in population databases (rs794727222, gnomAD 0.003%). This variant has not been reported in the literature in individuals affected with ATP1A2-related conditions. ClinVar contains an entry for this variant (Variation ID: 194925). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ATP1A2 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |